VRCA
Verrica Pharmaceuticals Inc.
$4.46
+$0.07(+1.59%)
18
Overall
--
Value
18
Tech
--
Quality
Market Cap
$41.66M
Volume
270.52K
52W Range
$3.82 - $18.20
Target Price
$15.00
Order:
Income Statement
| Metric | Trend | Chart | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | -- | -- | -- | $12.0M | $9.0M | $5.1M | $7.6M | ||
| Total Revenue | -- | -- | -- | $12.0M | $9.0M | $5.1M | $7.6M | ||
| COST OF GOODS SOLD | |||||||||
| Cost of Revenue | -- | -- | -- | -- | $725.0K | $500.0K | $2.7M | ||
| GROSS PROFIT | |||||||||
| Gross Profit | -- | -- | -- | $12.0M | $8.3M | $5.1M | $7.6M | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $-21.9M | $30.1M | $40.2M | $42.9M | $30.3M | $70.9M | $73.5M | ||
| Research & Development | $12.8M | $15.4M | $15.7M | $15.9M | $12.2M | $20.3M | $11.8M | ||
| Research Expense | $12.8M | $15.4M | $15.7M | $15.9M | $12.2M | $20.3M | $11.8M | ||
| Selling, General & Administrative | $9.1M | $14.6M | $24.5M | $27.0M | $17.4M | $47.3M | $58.8M | ||
| Selling & Marketing Expenses | -- | -- | -- | -- | -- | $3.5M | $4.3M | ||
| General & Administrative Expenses | $9.1M | $14.6M | $24.5M | $27.0M | $17.4M | $47.3M | $58.8M | ||
| Promotion & Advertising | -- | -- | -- | -- | -- | $3.5M | $4.3M | ||
| Salaries & Wages | $-2.3M | $-3.3M | -- | -- | -- | $14.4M | $7.2M | ||
| Depreciation & Amortization | $-20.3K | $-64.2K | $43.0K | $244.0K | $500.0K | $500.0K | $300.0K | ||
| Depreciation & Amortization | $-20.3K | $-64.2K | $43.0K | $244.0K | $500.0K | $500.0K | $300.0K | ||
| Amortization | $-435.0K | -- | -- | $5.0K | $4.0K | $20.0K | -- | ||
| Other Operating Expenses | $1.0K | $4.0K | $186.0K | $367.0K | $-725.0K | $282.0K | $387.0K | ||
| OPERATING INCOME | |||||||||
| Operating income | $-21.9M | $-30.1M | $-40.2M | $-30.9M | $-21.3M | $-65.8M | $-65.9M | ||
| EBITDA | $-21.1M | $-29.0M | $-39.4M | $-30.3M | $-21.6M | $-67.7M | $-69.5M | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | -- | -- | $3.0M | $4.3M | $2.2M | $7.0K | $9.4M | ||
| Intinc | $1.2M | $1.9M | $521.0K | $123.0K | $476.0K | $2.7M | $1.4M | ||
| Net Non-Operating Interest Income/Expense | $1.2M | $1.9M | $-2.5M | $-4.2M | $-1.7M | $2.7M | $1.4M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | -- | $-2.6M | ||
| Other Income/Expense | -- | -- | -- | -- | $-1.5M | $2.6M | $2.7M | ||
| Other Special Charges | -- | -- | -- | -- | $-1.5M | $-14.0K | $-17.0K | ||
| SPECIAL ITEMS | |||||||||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | $2.6M | $100.0K | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-20.6M | $-28.2M | $-39.7M | $-30.8M | $-22.3M | $-68.5M | $-69.8M | ||
| Pre-Tax Income | $-20.6M | $-28.2M | $-42.7M | $-35.1M | $-24.5M | $-62.3M | $-76.6M | ||
| INCOME TAX | |||||||||
| Tax Provision | -- | -- | $-2.9M | $-2.7M | $-955.0K | $-1.5M | $-2.6M | ||
| NET INCOME | |||||||||
| Net Income | $-20.6M | $-28.2M | $-42.7M | $-35.1M | $-24.5M | $-67.0M | $-76.6M | ||
| Net Income (Continuing Operations) | $-20.6M | $-28.2M | $-42.7M | $-35.1M | $-24.5M | $-67.0M | $-76.6M | ||
| Net Income (Discontinued Operations) | $-20.6M | $-28.2M | $-42.7M | $-35.1M | $-24.5M | $-67.0M | $-76.6M | ||
| Net Income (Common Stockholders) | $-20.6M | $-28.2M | $-42.7M | $-35.1M | $-24.5M | $-62.3M | $-76.6M | ||
| Normalized Income | -- | -- | -- | $-37.8M | -- | -- | $-66.8M | ||
| TOTALS | |||||||||
| Total Expenses | $-21.9M | $30.1M | $40.2M | $42.9M | $30.3M | $71.4M | $76.1M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $1.5M | $2.5M | $2.5M | $2.7M | $3.4M | $4.5M | $51.8M | ||
| Average Shares Outstanding (Diluted) | $1.5M | $2.5M | $2.5M | $2.7M | $3.4M | $4.5M | $51.8M | ||
| Shares Outstanding | $2.6M | $2.6M | $2.5M | $2.8M | $4.2M | $4.2M | $91.8M | ||
| Basic EPS | -- | -- | $-17.1 | $-13 | $-7.2 | $-14.8 | $-1.48 | ||
| Basic EPS (Continuing Operations) | -- | -- | $-17.1 | $-13 | $-7.2 | $-14.8 | $-1.48 | ||
| Diluted EPS | $-14.1 | $-11.3 | $-17.1 | $-13 | $-7.2 | $-14.8 | $-1.48 | ||
| Diluted EPS (Continuing Operations) | -- | $-11.3 | -- | -- | $-7.2 | $-14.8 | $-1.48 | ||
| OTHER METRICS | |||||||||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | $-2.5M | $-83.0K | ||
| Other Gand A | $9.1M | $14.6M | $24.5M | $27.0M | $17.4M | $47.3M | $58.8M | ||
| Rent And Landing Fees | $9.1M | $-228.0K | $186.0K | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VRCA | $4.46 | +1.6% | 270.52K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Verrica Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW